About Prosensa
Prosensa is a Healthcare company based in Leiden (Netherlands) founded in 2002, and was acquired by BioMarin Pharmaceutical in November 2014. RNA-modulating therapeutics for neuromuscular disorders were developed. Prosensa has raised $72.62 million across 4 funding rounds from investors including BioMarin Pharmaceutical, Idinvest Partners and Gimv. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is Prosensa Holding N.V.
Company details
Prosensa was founded in 2002 in Leiden, Netherlands, within the biotechnology sector. Focus was placed on RNA-modulating therapeutics for neuromuscular disorders, including the lead compound drisapersen, an oligonucleotide targeting dystrophin RNA splicing for Duchenne muscular dystrophy across seven programs. Preclinical candidates were advanced for Huntingtons disease and myotonic dystrophy. Acquisition by BioMarin occurred in November 2014.
- Headquarters Leiden, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website prosensa.eu
- Social LinkedIn X
- Acquired by BioMarin Pharmaceutical (Nov 2014)
- Legal Name Prosensa Holding N.V.
- Total Equity Funding$72.62M (USD)
in 4 rounds
- Latest Funding Round$200K (USD), Grant
Jun 2014
- InvestorsBioMarin Pharmaceutical
& 7 more
- Acquired byBioMarin Pharmaceutical
(Nov 2014)
Funding Insights of Prosensa
Prosensa has successfully raised a total of $72.62M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $200 thousand completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.62M
- Total Rounds 4
- Last Round Grant — $200,000
- First Round $18M
(Feb 2007)
- Investors Count 7
All 4 funding rounds of Prosensa with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $200,000 | Grant | – | – | |
| Jan 2012 | $29.92M | Series C | – | New Enterprise Associates | |
| Dec 2008 | $24.7M | Series B | – | – | |
| Feb 2007 | $18M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Prosensa
Prosensa has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, Idinvest Partners and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Venture capital is provided to medical life sciences companies. | medsciencescapital.com | The Hague, Netherlands | ||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Foundation funding is provided to combat muscular dystrophy. | 1994 | parentprojectmd.org | Hackensack, United States | |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for Prosensa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prosensa
4 dated milestones of Prosensa across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Prosensa is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Grant, of $200K.
- Exit Acquired by BioMarin Pharmaceutical.
Web traffic of Prosensa
Websites that share an audience with Prosensa (prosensa.eu).
Websites whose visitors overlap most with Prosensa. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| profibrix.com | 100% | View details | |||
| esperion.com | 96% | 16.4K | #1,899,294 | View details | |
| gsk.com | 69% | 1.3M | #56,834 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prosensa
Complete news archive for Prosensa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosensa
Prosensa was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Prosensa is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Prosensa is a funded company, having raised a total of $72.62M across 4 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Feb 2007.
Prosensa was founded in 2002 in Leiden, Netherlands, within the biotechnology sector. Focus was placed on RNA-modulating therapeutics for neuromuscular disorders, including the lead compound drisapersen, an oligonucleotide targeting dystrophin RNA splicing for Duchenne muscular dystrophy across seven programs. Preclinical candidates were advanced for Huntingtons disease and myotonic dystrophy. Acquisition by BioMarin occurred in November 2014.
Prosensa has 8 investors. Key investors include BioMarin Pharmaceutical, Idinvest Partners, Gimv, Abingworth, and Life Sciences Partners.
Prosensa operates through Prosensa Holding N.V..
Yes. Prosensa was acquired by BioMarin Pharmaceutical in November 2014.